Sun Pharma analysts see stock testing ₹2,400 levels; Should you buy or sell?

Share it

Out of the 41 analysts that have coverage on Sun Pharma, 30 of them have a ‘Buy’ rating on the stock. Seven of them have a ‘Hold’ rating, while only four of them have a ‘Sell’ recommendation.

Leave a Comment

Your email address will not be published. Required fields are marked *